Tag: peptic ulcer market research

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Peptic Ulcer Market from 2024 to 2033?

The peptic ulcer market grew from $3.94 billion in 2023 to $4.1 billion in 2024, at a CAGR of 4.0%, due to Helicobacter pylori prevalence, NSAID usage, lifestyle changes, educational campaigns, and stress management focus.

The peptic ulcer market is expected to grow to $4.69 billion by 2028, with a CAGR of 3.5%. Growth is attributed to emerging therapies, an aging population, precision medicine integration, preventive health measures, and ongoing research. Major trends include digital health solutions, treatment modality advancements, rising Helicobacter pylori infections, and combination therapies.

Claim Your Free Sample of the Global Peptic Ulcer Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13221&type=smp

What Key Factors Are Fueling the Growth of the Peptic Ulcer Market?

The increasing prevalence of obesity is expected to contribute to the growth of the peptic ulcer market. Obesity, a condition characterized by excessive body fat, often results from poor diet and lack of exercise. It leads to the overproduction of stomach acid, weakening the stomach’s protective lining and contributing to peptic ulcers. The World Obesity Atlas reported in March 2022 that the global number of people with obesity reached 764 million in 2020 and is projected to grow to 892 million by 2025. This rise in obesity rates is fueling the market.

What Are the Major Segments of the Peptic Ulcer Market?

1) By Disease Indication: Gastritis, Gastric Ulcer, Duodenal Ulcer, Gastroesophageal Reflux Disease (GERD)

2) By Drug Type: Proton Pump Inhibitors (PPI), H2 Antagonists, Antibiotics, Other Drugs

3) By Distribution Channel: Hospital Pharmacies, Private Clinics, Drug Store, Retail Pharmacies, E-commerce

What New Trends Are Transforming the Peptic Ulcer Market?

In the peptic ulcer market, companies are developing and gaining approval for new drugs to treat peptic ulcers effectively. Drug development is essential for managing symptoms and preventing complications. Dartisla ODT, approved by the U.S. FDA in December 2021, is a new drug for peptic ulcer treatment. This oral medication has anticholinergic properties and contains 1.7 mg of glycopyrrolate, helping reduce symptoms associated with peptic ulcers.

Order Now for Fast Delivery of Your Peptic Ulcer Market Report!

https://www.thebusinessresearchcompany.com/report/peptic-ulcer-global-market-report

Which Regions Are Driving Growth in the Peptic Ulcer Market?

North America was the largest region in the peptic ulcer market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptic ulcer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Peptic Ulcer Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the peptic ulcer market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Peptic Ulcer Market Include

1. Peptic Ulcer Market Executive Summary

2. Peptic Ulcer Market Segments

3. Peptic Ulcer Market Size And Template Market Growth Rate

4. Key Peptic Ulcer Market Trends

5. Major Peptic Ulcer Market Drivers

……

25. Key Mergers And Acquisitions In The Peptic Ulcer Market

26. Top Peptic Ulcer Companies

27. Peptic Ulcer Market Opportunities And Strategies

28. Peptic Ulcer Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Diabetic Foot Ulcer Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-global-market-report

Diabetic Foot Ulcer Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/diabetic-foot-ulcer-treatment-global-market-report

Ulcerative Colitis Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s market reports offer an in-depth analysis on the market’s growth potential, major drivers, key trends and more.

• Growing Prevalence of Obesity: Obesity characterized by excessive body fat accumulation.
• Link to Peptic Ulcers: Obesity leads to overproduction of stomach acid and weakens mucosal lining.
• Global Obesity Statistics: Estimated global obesity to increase from 764 million in 2020 to 892 million by 2025.
• Impact on Market Growth: Rising obesity rates drive the growth of the peptic ulcer market.

Advancements In Peptic Ulcer Treatment With Dartisla ODT’s FDA Approval

• Importance of Drug Development: Crucial for managing symptoms, healing, and preventing complications.
• FDA Approval of Dartisla ODT: Approved in December 2021, aids in symptom management.
• Mechanism of Action: Contains glycopyrrolate with anticholinergic properties.
• Significance: First medication approved as a supplement for peptic ulcer treatment.

Juvisé Pharmaceuticals Acquires Global Rights Of Pylera From AbbVie For Enhancing Gastro-Intestinal Medicine Portfolio

• Acquisition Details: Juvisé acquires Pylera from AbbVie for $408 million.
• Purpose: Expansion of gastro-intestinal medicine portfolio.
• Pylera Function: Antimicrobial tri-therapy for H. pylori infection-induced peptic ulcers.
• Strategic Importance: Aligns with Juvisé’s geographic expansion and product portfolio enhancement.

Read More On The Peptic Ulcer Market Report 2024 – https://www.thebusinessresearchcompany.com/report/peptic-ulcer-global-market-report

Market Segmentation and Growth Trends

• Segmentation:
  1. By Disease Indication: Gastritis, Gastric Ulcer, Duodenal Ulcer, GERD
  2. By Drug Type: PPI, H2 Antagonists, Antibiotics, Other Drugs
  3. By Distribution Channel: Hospital Pharmacies, Private Clinics, Drug Store, Retail Pharmacies, E-commerce
• Regional Outlook:

• • North America: Largest market in 2023.
  • Asia-Pacific: Expected to be the fastest-growing region in the forecast period.

The peptic ulcer market has seen steady growth in recent years, driven by various factors influencing both historic and forecast periods. The market’s growth trajectory is a result of a multitude of factors contributing to the prevalence and treatment landscape of peptic ulcers.

Historic Growth Factors

• Increased prevalence of Helicobacter pylori infection.
• Rising use of nonsteroidal anti-inflammatory drugs (NSAIDs).
• Changing lifestyles and dietary habits.
• Awareness campaigns and educational initiatives.
• Focus on stress management.

Forecast Growth Factors

• Emerging therapies and treatment modalities.
• Increasing geriatric population.
• Integration of precision medicine.
• Preventive measures and health promotion.
• Continued research and clinical trials.

Key Trends in Forecast Period

• Digital health solutions.
• Advancements in treatment modalities.
• Increasing prevalence of Helicobacter pylori infection.
• Integration of diagnostic imaging technologies.
• Increasing use of combination therapies.

As obesity becomes increasingly prevalent globally, it serves as a significant driver for the expansion of the peptic ulcer market. The correlation between obesity and the development of peptic ulcers underscores the importance of addressing lifestyle factors in managing and preventing this condition.

Moreover, advancements in treatment options, such as the FDA approval of Dartisla ODT, and strategic acquisitions, like Juvisé Pharmaceuticals acquiring Pylera, indicate a dynamic landscape characterized by innovation and strategic partnerships.

In conclusion, the peptic ulcer market continues to evolve, propelled by a combination of market drivers, treatment innovations, and strategic maneuvers within the pharmaceutical industry. With a robust forecast for growth and ongoing efforts to address underlying causes and improve treatment outcomes, the market presents opportunities for stakeholders to contribute to better patient outcomes and drive continued advancement in peptic ulcer management.

 Request for A Sample Of The Global Peptic Ulcer Market Report:
https://www.thebusinessresearchcompany.com/sample_request?id=13221&type=smp